In vivo science and artificial intelligence join forces to advance tools in cancer treatment and management

It will become easier to discover imaging biomarkers and identify digital surrogates for modern end-points in personalized therapies, thanks to a partnership between Sylvain Meloche – Principal Investigator within the signaling and cell growth research unit at the Institute for Research in Immunology and Cancer (IRIC) – along with his team, and Imagia, an AI-driven personalized healthcare company.

Press Apr 21, 2022

Digital Technology Supercluster Announces Investment to Increase the Effectiveness of Precision Oncology

Harnessing artificial intelligence to take the guesswork out of diagnosing cancer recurrence for millions of cancer survivors

Blog Apr 4, 2022

How to Bring Biomarker Testing In-House for Cancer Targeted Treatment Selection

Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advan

...

Press Feb 9, 2022

Imagia Cybernetics & Canexia Health Merge to Supercharge Precision Oncology Accessibility

Imagia Cybernetics, an AI-healthcare company that accelerates oncology solutions generated from real world data, today announced its merger

...

In vivo science and artificial intelligence join forces to advance tools in cancer treatment and management

Related posts

Request info